Synergistic Effects of Thalidomide and Cisplatin Are Mediated Via the PI3K/AKT and JAK1/STAT3 Signaling Pathways in Cervical Cancer

Overview

Journal Oncol Rep

Specialty Oncology

Date 2022 Aug 3

PMID 35920185

Authors

Cairu Liu

Haiqin Feng

Lihong Song

Shuirui Li

Yiping Wu

Liping Yang

Affiliations

Soon will be listed here.

Abstract

Thalidomide (THD) has been found to synergize with cisplatin (DDP) in certain types of cancers; however, their combined use in the treatment of cervical cancer has not been reported to date, at least to the best of our knowledge. Thus, the present study aimed to explore the synergistic effects of THD and DDP and determine their regulatory effects on the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT) and Janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3) pathways in cervical cancer. For this purpose, 0‑160 µM THD and 0‑64 µM DDP monotherapy or in combination were used to treat the HeLa and SiHa cervical cancer cell lines. This was followed by the calculation of the combination index (CI) and 160 µM THD and 16 µM DDP were then used to treat the cells. Relative cell viability and apoptosis, as well as the mRNA and protein levels of PI3K, AKT, JAK1 and STAT3 were evaluated. The results revealed that THD and DDP monotherapy suppressed the viability of the HeLa and SiHa cells in a concentration‑dependent manner. Moreover, THD and DDP treatment exerted a more prominent suppressive effect on the relative viability of HeLa and SiHa cells compared with DDP monotherapy at several concentration settings; further CI calculation revealed that the optimal synergistic concentrations were 160 µM for THD and 16 µM for DDP. Subsequently, combined treatment with THD and DDP suppressed relative cell viability, whereas it promoted cell apoptosis compared with THD or DPP monotherapy; it also inhibited the PI3K/AKT and JAK1/STAT3 signaling pathways compared with DPP or THD monotherapy in both HeLa and SiHa cells. On the whole, the present study demonstrated that THD synergizes with DDP to exert suppressive effects on cervical cancer cell lines. This synergistic action also inactivated the PI3K/AKT and JAK1/STAT3 pathways. Thus, these findings suggest that the combined use of THD and DPP may have potential for use in the treatment of cervical cancer.

Citing Articles

The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.

Li G, Che X, Wang S, Liu D, Xie D, Jiang B Ann Med. 2025; 57(1):2447403.

PMID: 39757995 PMC: 11705547. DOI: 10.1080/07853890.2024.2447403.

[High LINC00626 expression promotes esophagogastric junction adenocarcinoma metastasis: the mediating role of the JAK1/STAT3/KHSRP axis].

Zhang F, Fan L, Kang X, Wei H, Li L Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(3):541-552.

PMID: 38597446 PMC: 11006707. DOI: 10.12122/j.issn.1673-4254.2024.03.16.

Network-based drug repurposing for HPV-associated cervical cancer.

Ahmed F, Yang Y, Samantasinghar A, Kim Y, Ko J, Choi K Comput Struct Biotechnol J. 2023; 21:5186-5200.

PMID: 37920815 PMC: 10618120. DOI: 10.1016/j.csbj.2023.10.038.

References

Murphy S, Davey R, Gu X, Haywood M, McCann L, Mather L . Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. J Neurooncol. 2007; 85(2):181-9. DOI: 10.1007/s11060-007-9406-3. View

Tamalunas A, Sauckel C, Ciotkowska A, Rutz B, Wang R, Huang R . Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?. Prostate. 2021; 81(7):377-389. DOI: 10.1002/pros.24114. View

Zhang L, Wu J, Ling M, Zhao L, Zhao K . The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015; 14:87. PMC: 4498560. DOI: 10.1186/s12943-015-0361-x. View

Downs Jr L, Rogers L, Yokoyama Y, Ramakrishnan S . Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer. Gynecol Oncol. 2005; 98(2):203-10. DOI: 10.1016/j.ygyno.2005.04.023. View

Koh W, Abu-Rustum N, Bean S, Bradley K, Campos S, Cho K . Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(1):64-84. DOI: 10.6004/jnccn.2019.0001. View

Zhong W, Wang Q, Mao W, Xu S, Wu L, Shen Y . Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2017; 19(1):139-148. DOI: 10.1016/S1470-2045(17)30729-5. View

Zheng X, Zhu Y, Wang X, Hou Y, Fang Y . Silencing of ITGB6 inhibits the progression of cervical carcinoma via regulating JAK/STAT3 signaling pathway. Ann Transl Med. 2021; 9(9):803. PMC: 8246156. DOI: 10.21037/atm-21-1669. View

Cochicho D, Esteves S, Rito M, Silva F, Martins L, Montalvao P . PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival. Cancers (Basel). 2022; 14(5). PMC: 8909011. DOI: 10.3390/cancers14051286. View

Morgan E, Chen Z, Van Waes C . Regulation of NFκB Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?. Cancers (Basel). 2020; 12(10). PMC: 7601648. DOI: 10.3390/cancers12102877. View

10.

Yang Y, Yang Z, Zhang R, Jia C, Mao R, Mahati S . MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway. Biosci Rep. 2021; 41(12). PMC: 8661504. DOI: 10.1042/BSR20192007. View

11.

Chen L, Qiu X, Wang R, Xie X . The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review. Sci Rep. 2014; 4:4818. PMC: 5381221. DOI: 10.1038/srep04818. View

12.

Vu M, Yu J, Awolude O, Chuang L . Cervical cancer worldwide. Curr Probl Cancer. 2018; 42(5):457-465. DOI: 10.1016/j.currproblcancer.2018.06.003. View

13.

Khezri M, Jafari R, Yousefi K, Zolbanin N . The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol. 2022; 127:104787. DOI: 10.1016/j.yexmp.2022.104787. View

14.

Lee J, Chung K, Lee H, Ko D, Kang M, Yoo H . Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells. Biomed Pharmacother. 2021; 142:111961. DOI: 10.1016/j.biopha.2021.111961. View

15.

Che Y, Li Y, Zheng F, Zou K, Li Z, Chen M . TRIP4 promotes tumor growth and metastasis and regulates radiosensitivity of cervical cancer by activating MAPK, PI3K/AKT, and hTERT signaling. Cancer Lett. 2019; 452:1-13. DOI: 10.1016/j.canlet.2019.03.017. View

16.

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T . Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol. 2015; 33(19):2129-35. DOI: 10.1200/JCO.2014.58.4391. View

17.

Yan C, Zhao Y, Cai H, Miao G, Ma W . Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A. Oncol Rep. 2015; 33(4):1737-44. DOI: 10.3892/or.2015.3769. View

18.

Coen J, Zhang P, Saylor P, Lee C, Wu C, Parker W . Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2018; 37(1):44-51. PMC: 6354769. DOI: 10.1200/JCO.18.00537. View

19.

Shen Y, Li S, Wang X, Wang M, Tian Q, Yang J . Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin. J Exp Clin Cancer Res. 2019; 38(1):427. PMC: 6816178. DOI: 10.1186/s13046-019-1366-x. View

20.

Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos M . Thalidomide in cancer medicine. Ann Oncol. 2004; 15(8):1151-60. DOI: 10.1093/annonc/mdh300. View